Postprandial HyperglycemiaSURE-BloGNCT06714552
Effect of a Sugar Replacement on Blood Glucose Levels in Healthy Adults
A study testing Galacto-Oligosaccharide and Glucose in people with Postprandial Hyperglycemia and Hyperinsulinemia, run by University of Aberdeen at 1 site in United Kingdom.
Trial summary
Diabetes and cardiovascular disease account for millions of deaths per year. One of the risk factors for both conditions is high blood sugar, particularly after eating (postprandial hyperglycaemia). Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Postprandial Hyperglycemia, Hyperinsulinemia
- What is being tested?
- Galacto-Oligosaccharide and Glucose
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 17 Jan 2025to 31 Jul 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Healthy Men or Women
- Body Mass Index (BMI) 18.5-29.9 kg/m^2
- Between 18 and 65 years of age
- Compliant (i.e., understands and is willing, able, and likely to comply with the experimental procedure and safety guidelines)
- Able to provide informed consent
- Premenopausal women must have a regular cycle or be on hormonal contraception.
Who cannot join
- Diabetes mellitus (all types including gestational diabetes)
- HbA1c result over the study limit [healthy range of between 4% and 5.9%]
- Endocrine disease (e.g., Cushing's syndrome)
- Any food allergy or intolerance, or following Vegan diet
- Medications that increase blood glucose (e.g., steroids, protease inhibitors, antipsychotics, antihypertensives, statins, diuretics, nicotinic acid, etc.)
- Medications that lower glycemia (e.g., anti-hyperglycaemics, insulin, beta- blockers, etc.)
Show all 14Show fewer
- Medication affecting glucose regulation, appetite, and/or digestion/absorption of nutrients, antibiotics
- Major medical or surgical event requiring hospitalization in the previous 3 months
- Pregnant or lactating
- Participation in another clinical/supplementation trial or actively trying to reduce body weight
- Unable to comply with experimental procedures and safety guidelines
- Unable to give consent
- Smokers
- Travel during the study period
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site
University of Aberdeen, Rowett Institute
Aberdeen, AB25 2ZD
About this study
Official title: Effect of the Replacement of Glycaemic Carbohydrates With Galacto-Oligosaccharide (GOS) Supplementation on Postprandial Glycaemic Response in Healthy Adults
Diabetes and cardiovascular disease account for millions of deaths per year. One of the risk factors for both conditions is high blood sugar, particularly after eating (postprandial hyperglycaemia). Lowering blood sugar levels after a meal is expected to have a positive effect on preventing metabolic and cardiovascular diseases and improving the metabolic control of those who already suffer from these conditions.
The aim of this study is to investigate the effect of Oligomate® (beta-galacto-oligosaccharide) on postprandial glycaemia when used as a partial replacement of glycaemic carbohydrates in a beverage in otherwise healthy volunteers. Volunteers will be given water with either Oligomate® or glucose (control) added. Blood samples will be collected at eight time points (two before drinking the beverage and six after) to measure glucose and insulin levels.
Read the detailed description
A single-centre, single-blind, randomised, controlled, cross-over, acute feeding trial will be conducted. The recruitment and study visits will be carried out at the Human Intervention Studies Unit (HISU) of the Rowett Institute.
A recruitment visit will be scheduled to screen for eligibility. During the visit, informed consent will be obtained before volunteers complete a health questionnaire, have their height and weight measured, and their veins checked to assess suitability for blood sample collection. A finger prick blood sample will then be taken to measure HbA1c levels. If a volunteer is eligible, the first study visit will be scheduled and they will be asked to fast for 12 hours the night before. A frozen high carbohydrate vegetarian ready-meal will be provided, which they will consume at home the evening before the study visit and before the fasting period.
During the study visits, the postprandial glycaemic response will be measured immediately after consumption of the supplement or control on two occasions separated by a wash-out period of 7-14 days. Briefly, subjects will arrive in the morning after having consumed the high carbohydrate meal the night before, followed by a 12 hr overnight fast. After recording body weight, a cannula will be inserted into an antecubital vein of one arm by a trained cannulist to allow repeated blood sampling during the assessment (approx. 6 ml collected per sample time to a total of 48 ml per visit). After obtaining two initial fasting blood samples (at -10min and -5min), subjects will consume the test beverage within 5 min. Further blood samples will be obtained at 15, 30, 45, 60, 90 and 120 min after ingestion to complete the postprandial glycaemic response assessment.
At the end of the first visit volunteers will receive the second ready-meal, identical to the first, which they will be asked to consume the evening before the second study visit, before the fasting period commences. During the second study visit, participants will consume the same beverage with the alternate supplement and complete the opposite arm of the postprandial glycaemic response assessment.
- Conditions
- Postprandial Hyperglycemia, Hyperinsulinemia
- Being tested
- Galacto-Oligosaccharide, Glucose
- Keywords
- galacto-oligosaccharides, postprandial glycaemia, GOS
- Medical subject headings
- Hyperglycemia, Hyperinsulinism
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Galacto-OligosaccharideDietary supplement
24.0 g Oligomate® in 100 mL water
GlucoseOther
17.8 g glucose in 100 mL water
| Study group | Role | What they receive |
|---|---|---|
| Beta-galacto-oligosaccharide | Experimental | Not described Receives: Dietary Supplement: Galacto-Oligosaccharide |
| Glucose | Other | Control Receives: Other: Glucose |
What is being measured
The primary outcome is the main question the study is designed to answer.
Difference in plasma glucose incremental area under the curve (iAUC) between study arms
Plasma glucose levels obtained from blood samples collected before and after beverage consumption will be determined using an automated clinical analyser. iAUC will be calculated using the trapezoidal rule with the baseline value of fasting plasma glucose subtracted.
Measured: 10 and 5 min before beverage consumption, 15, 30, 45, 60, 90, 120 min after beverage consumption
Secondary outcomes (6)
Difference in plasma glucose total area under the curve (tAUC) between study arms
Plasma glucose levels obtained from blood samples collected before and after beverage consumption will be determined using an automated clinical analyser. tAUC will be calculated using the trapezoidal rule with zero as the baseline.
Measured: 10 and 5 min before beverage consumption, 15, 30, 45, 60, 90, 120 min after beverage consumption
Difference in peak plasma glucose concentration between study arms
Plasma glucose levels obtained from blood samples collected before and after beverage consumption will be determined using an automated clinical analyser. The peak plasma glucose concentrations for each arm will be compared.
Measured: 10 and 5 min before beverage consumption, 15, 30, 45, 60, 90, 120 min after beverage consumption
Measured maximal incremental glucose value (iCMax) between study arms
Plasma glucose levels obtained from blood samples collected before and after beverage consumption will be determined using an automated clinical analyser. iCMax will be calculated using fasting plasma glucose levels as baseline.
Measured: 10 and 5 min before beverage consumption, 15, 30, 45, 60, 90, 120 min after beverage consumption
Difference in plasma insulin iAUC between study arms
Plasma insulin levels will be determined using ELISA from blood samples obtained, at several time points.
iAUC will be calculated using the trapezoidal rule with baseline value of fasting plasma insulin subtracted.
Measured: baseline, 30, 60, 120 min after beverage consumption
Difference in plasma insulin tAUC between study arms
Plasma insulin levels will be determined using ELISA from blood samples obtained at several time points. tAUC will be calculated using the trapezoidal rule with zero as the baseline.
Measured: baseline, 30, 60, 120 min after beverage consumption
Difference in peak plasma insulin concentration between study arms
Plasma insulin will be determined using ELISA from blood samples obtained at several time points. Peak plasma insulin levels for each arm will be compared.
Measured: baseline, 30, 60, 120 min after beverage consumption
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Dec 2024
- Study start17 Jan 2025
- Primary completion13 Apr 2026
- Study completion31 Jul 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (18)Papers the sponsor has linked to this study.
- Other trials for Postprandial HyperglycemiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 50 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Aberdeen
- Sponsor type
- University, hospital or other
- Collaborators
- Yakult Honsha Co., LTD
- Responsible party
- Sponsor
- Investigators
- Karen Scott, PhD, Principal investigator, University of Aberdeen
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06714552
- Sponsor's protocol ID
- SURE-BloG
- Acronym
- SURE-BloG
- Status last verified
- May 2026
- First submitted
- 21 Nov 2024
- Last updated
- 18 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: The study is designed to look at average responses to the supplement. There is no need to share individual participant data.
Publications
Venn BJ, Green TJ. Glycemic index and glycemic load: measurement issues and their effect on diet-disease relationships. Eur J Clin Nutr. 2007 Dec;61 Suppl 1:S122-31. doi: 10.1038/sj.ejcn.1602942.
PubMed 17992183Wright E Jr, Scism-Bacon JL, Glass LC. Oxidative stress in type 2 diabetes: the role of fasting and postprandial glycaemia. Int J Clin Pract. 2006 Mar;60(3):308-14. doi: 10.1111/j.1368-5031.2006.00825.x.
PubMed 16494646Blaak EE, Antoine JM, Benton D, Bjorck I, Bozzetto L, Brouns F, Diamant M, Dye L, Hulshof T, Holst JJ, Lamport DJ, Laville M, Lawton CL, Meheust A, Nilson A, Normand S, Rivellese AA, Theis S, Torekov SS, Vinoy S. Impact of postprandial glycaemia on health and prevention of disease. Obes Rev. 2012 Oct;13(10):923-84. doi: 10.1111/j.1467-789X.2012.01011.x. Epub 2012 Jul 11.
PubMed 22780564Neri S, Calvagno S, Mauceri B, Misseri M, Tsami A, Vecchio C, Mastrosimone G, Di Pino A, Maiorca D, Judica A, Romano G, Rizzotto A, Signorelli SS. Effects of antioxidants on postprandial oxidative stress and endothelial dysfunction in subjects with impaired glucose tolerance and type 2 diabetes. Eur J Nutr. 2010 Oct;49(7):409-16. doi: 10.1007/s00394-010-0099-6. Epub 2010 Mar 7.
PubMed 20213326Bonora E. Postprandial peaks as a risk factor for cardiovascular disease: epidemiological perspectives. Int J Clin Pract Suppl. 2002 Jul;(129):5-11.
PubMed 12166607Levitan EB, Song Y, Ford ES, Liu S. Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Arch Intern Med. 2004 Oct 25;164(19):2147-55. doi: 10.1001/archinte.164.19.2147.
PubMed 15505129Lin PJ, Borer KT. Third Exposure to a Reduced Carbohydrate Meal Lowers Evening Postprandial Insulin and GIP Responses and HOMA-IR Estimate of Insulin Resistance. PLoS One. 2016 Oct 31;11(10):e0165378. doi: 10.1371/journal.pone.0165378. eCollection 2016.
PubMed 27798656Hinnen DA. Therapeutic Options for the Management of Postprandial Glucose in Patients With Type 2 Diabetes on Basal Insulin. Clin Diabetes. 2015 Oct;33(4):175-80. doi: 10.2337/diaclin.33.4.175.
PubMed 26487791Kamruzzaman M, Horowitz M, Jones KL, Marathe CS. Gut-Based Strategies to Reduce Postprandial Glycaemia in Type 2 Diabetes. Front Endocrinol (Lausanne). 2021 Apr 9;12:661877. doi: 10.3389/fendo.2021.661877. eCollection 2021.
PubMed 33897622Gill SK, Rossi M, Bajka B, Whelan K. Dietary fibre in gastrointestinal health and disease. Nat Rev Gastroenterol Hepatol. 2021 Feb;18(2):101-116. doi: 10.1038/s41575-020-00375-4. Epub 2020 Nov 18.
PubMed 33208922Jenkins DJ, Goff DV, Leeds AR, Alberti KG, Wolever TM, Gassull MA, Hockaday TD. Unabsorbable carbohydrates and diabetes: Decreased post-prandial hyperglycaemia. Lancet. 1976 Jul 24;2(7978):172-4. doi: 10.1016/s0140-6736(76)92346-1.
PubMed 73796Bonsu NKA, Johnson S. Effects of inulin fibre supplementation on serum glucose and lipid concentration in patients with type 2 diabetes. International Journal of Diabetes and Metabolism. 2012 12;20(3):80-6. doi: 10.1159/000497730.
Dehghan P, Pourghassem Gargari B, Asgharijafarabadi M. Effects of high performance inulin supplementation on glycemic status and lipid profile in women with type 2 diabetes: a randomized, placebo-controlled clinical trial. Health Promot Perspect. 2013 Jun 30;3(1):55-63. doi: 10.5681/hpp.2013.007. eCollection 2013.
PubMed 24688953Luo J, Van Yperselle M, Rizkalla SW, Rossi F, Bornet FR, Slama G. Chronic consumption of short-chain fructooligosaccharides does not affect basal hepatic glucose production or insulin resistance in type 2 diabetics. J Nutr. 2000 Jun;130(6):1572-7. doi: 10.1093/jn/130.6.1572.
PubMed 10827212Gargari BP, Namazi N, Khalili M, Sarmadi B, Jafarabadi MA, Dehghan P. Is there any place for resistant starch, as alimentary prebiotic, for patients with type 2 diabetes? Complement Ther Med. 2015 Dec;23(6):810-5. doi: 10.1016/j.ctim.2015.09.005. Epub 2015 Sep 16.
PubMed 26645521
Study at a glance
From the registry record, last updated by the sponsor on 18 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of the Replacement of Glycaemic Carbohydrates With Galacto-Oligosaccharide (GOS) Supplementation on Postprandial Glycaemic Response in Healthy Adults
- ClinicalTrials.gov ID
- NCT06714552
- Acronym / sponsor ID
- SURE-BloG / SURE-BloG
- Conditions
- Postprandial Hyperglycemia, Hyperinsulinemia
- Keywords
- galacto-oligosaccharides, postprandial glycaemia, GOS
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 50 participants (actual)
- Lead sponsor
- University of AberdeenUniversity, hospital or other
- Collaborators
- Yakult Honsha Co., LTD
- Study start
- 17 Jan 2025 (actual)
- Primary completion
- 13 Apr 2026 (actual)
- Study completion
- 31 Jul 2026 (estimated)
- First posted
- 3 Dec 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Diabetes and cardiovascular disease account for millions of deaths per year. One of the risk factors for both conditions is high blood sugar, particularly after eating (postprandial hyperglycaemia). Lowering blood sugar levels after a meal is expected to have a positive effect on preventing metabolic and cardiovascular diseases and improving the metabolic control of those who already suffer from these conditions.
The aim of this study is to investigate the effect of Oligomate® (beta-galacto-oligosaccharide) on postprandial glycaemia when used as a partial replacement of glycaemic carbohydrates in a beverage in otherwise healthy volunteers. Volunteers will be given water with either Oligomate® or glucose (control) added. Blood samples will be collected at eight time points (two before drinking the beverage and six after) to measure glucose and insulin levels.
Detailed description
A single-centre, single-blind, randomised, controlled, cross-over, acute feeding trial will be conducted. The recruitment and study visits will be carried out at the Human Intervention Studies Unit (HISU) of the Rowett Institute.
A recruitment visit will be scheduled to screen for eligibility. During the visit, informed consent will be obtained before volunteers complete a health questionnaire, have their height and weight measured, and their veins checked to assess suitability for blood sample collection. A finger prick blood sample will then be taken to measure HbA1c levels. If a volunteer is eligible, the first study visit will be scheduled and they will be asked to fast for 12 hours the night before. A frozen high carbohydrate vegetarian ready-meal will be provided, which they will consume at home the evening before the study visit and before the fasting period.
During the study visits, the postprandial glycaemic response will be measured immediately after consumption of the supplement or control on two occasions separated by a wash-out period of 7-14 days. Briefly, subjects will arrive in the morning after having consumed the high carbohydrate meal the night before, followed by a 12 hr overnight fast. After recording body weight, a cannula will be inserted into an antecubital vein of one arm by a trained cannulist to allow repeated blood sampling during the assessment (approx. 6 ml collected per sample time to a total of 48 ml per visit). After obtaining two initial fasting blood samples (at -10min and -5min), subjects will consume the test beverage within 5 min. Further blood samples will be obtained at 15, 30, 45, 60, 90 and 120 min after ingestion to complete the postprandial glycaemic response assessment.
At the end of the first visit volunteers will receive the second ready-meal, identical to the first, which they will be asked to consume the evening before the second study visit, before the fasting period commences. During the second study visit, participants will consume the same beverage with the alternate supplement and complete the opposite arm of the postprandial glycaemic response assessment.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Beta-galacto-oligosaccharide | Experimental | Dietary Supplement: Galacto-Oligosaccharide |
| Glucose | Other | Other: GlucoseControl |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Healthy Men or Women
- Body Mass Index (BMI) 18.5-29.9 kg/m^2
- Between 18 and 65 years of age
- Compliant (i.e., understands and is willing, able, and likely to comply with the experimental procedure and safety guidelines)
- Able to provide informed consent
Key exclusion criteria (14 listed)
- Diabetes mellitus (all types including gestational diabetes)
- HbA1c result over the study limit [healthy range of between 4% and 5.9%]
- Endocrine disease (e.g., Cushing's syndrome)
- Any food allergy or intolerance, or following Vegan diet
- Medications that increase blood glucose (e.g., steroids, protease inhibitors, antipsychotics, antihypertensives, statins, diuretics, nicotinic acid, etc.)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Galacto-Oligosaccharide24.0 g Oligomate® in 100 mL water | Dietary supplement | Beta-galacto-oligosaccharide |
| Glucose17.8 g glucose in 100 mL water | Other | Glucose |
Primary outcome
Difference in plasma glucose incremental area under the curve (iAUC) between study arms
Time frame: 10 and 5 min before beverage consumption, 15, 30, 45, 60, 90, 120 min after beverage consumption
Plasma glucose levels obtained from blood samples collected before and after beverage consumption will be determined using an automated clinical analyser. iAUC will be calculated using the trapezoidal rule with the baseline value of fasting plasma glucose subtracted.
6 secondary outcomes
Difference in plasma glucose total area under the curve (tAUC) between study arms
Time frame: 10 and 5 min before beverage consumption, 15, 30, 45, 60, 90, 120 min after beverage consumption
Difference in peak plasma glucose concentration between study arms
Time frame: 10 and 5 min before beverage consumption, 15, 30, 45, 60, 90, 120 min after beverage consumption
Measured maximal incremental glucose value (iCMax) between study arms
Time frame: 10 and 5 min before beverage consumption, 15, 30, 45, 60, 90, 120 min after beverage consumption
Difference in plasma insulin iAUC between study arms
Time frame: baseline, 30, 60, 120 min after beverage consumption
Difference in plasma insulin tAUC between study arms
Time frame: baseline, 30, 60, 120 min after beverage consumption
Difference in peak plasma insulin concentration between study arms
Time frame: baseline, 30, 60, 120 min after beverage consumption
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Jun 2026.
- Background: PubMed 17992183Venn BJ, Green TJ. Glycemic index and glycemic load: measurement issues and their effect on diet-disease relationships. Eur J Clin Nutr. 2007 Dec;61 Suppl 1:S122-31. doi: 10.1038/sj.ejcn.1602942.
- Background: PubMed 16494646Wright E Jr, Scism-Bacon JL, Glass LC. Oxidative stress in type 2 diabetes: the role of fasting and postprandial glycaemia. Int J Clin Pract. 2006 Mar;60(3):308-14. doi: 10.1111/j.1368-5031.2006.00825.x.
- Background: PubMed 22780564Blaak EE, Antoine JM, Benton D, Bjorck I, Bozzetto L, Brouns F, Diamant M, Dye L, Hulshof T, Holst JJ, Lamport DJ, Laville M, Lawton CL, Meheust A, Nilson A, Normand S, Rivellese AA, Theis S, Torekov SS, Vinoy S. Impact of postprandial glycaemia on health and prevention of disease. Obes Rev. 2012 Oct;13(10):923-84. doi: 10.1111/j.1467-789X.2012.01011.x. Epub 2012 Jul 11.
- Background: PubMed 20213326Neri S, Calvagno S, Mauceri B, Misseri M, Tsami A, Vecchio C, Mastrosimone G, Di Pino A, Maiorca D, Judica A, Romano G, Rizzotto A, Signorelli SS. Effects of antioxidants on postprandial oxidative stress and endothelial dysfunction in subjects with impaired glucose tolerance and type 2 diabetes. Eur J Nutr. 2010 Oct;49(7):409-16. doi: 10.1007/s00394-010-0099-6. Epub 2010 Mar 7.
- Background: PubMed 12166607Bonora E. Postprandial peaks as a risk factor for cardiovascular disease: epidemiological perspectives. Int J Clin Pract Suppl. 2002 Jul;(129):5-11.
- Background: PubMed 15505129Levitan EB, Song Y, Ford ES, Liu S. Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Arch Intern Med. 2004 Oct 25;164(19):2147-55. doi: 10.1001/archinte.164.19.2147.
- Background: PubMed 27798656Lin PJ, Borer KT. Third Exposure to a Reduced Carbohydrate Meal Lowers Evening Postprandial Insulin and GIP Responses and HOMA-IR Estimate of Insulin Resistance. PLoS One. 2016 Oct 31;11(10):e0165378. doi: 10.1371/journal.pone.0165378. eCollection 2016.
- Background: PubMed 26487791Hinnen DA. Therapeutic Options for the Management of Postprandial Glucose in Patients With Type 2 Diabetes on Basal Insulin. Clin Diabetes. 2015 Oct;33(4):175-80. doi: 10.2337/diaclin.33.4.175.
- Background: PubMed 33897622Kamruzzaman M, Horowitz M, Jones KL, Marathe CS. Gut-Based Strategies to Reduce Postprandial Glycaemia in Type 2 Diabetes. Front Endocrinol (Lausanne). 2021 Apr 9;12:661877. doi: 10.3389/fendo.2021.661877. eCollection 2021.
- Background: PubMed 33208922Gill SK, Rossi M, Bajka B, Whelan K. Dietary fibre in gastrointestinal health and disease. Nat Rev Gastroenterol Hepatol. 2021 Feb;18(2):101-116. doi: 10.1038/s41575-020-00375-4. Epub 2020 Nov 18.
- Background: PubMed 73796Jenkins DJ, Goff DV, Leeds AR, Alberti KG, Wolever TM, Gassull MA, Hockaday TD. Unabsorbable carbohydrates and diabetes: Decreased post-prandial hyperglycaemia. Lancet. 1976 Jul 24;2(7978):172-4. doi: 10.1016/s0140-6736(76)92346-1.
- BackgroundBonsu NKA, Johnson S. Effects of inulin fibre supplementation on serum glucose and lipid concentration in patients with type 2 diabetes. International Journal of Diabetes and Metabolism. 2012 12;20(3):80-6. doi: 10.1159/000497730.
- Indicator Metadata Registry List: Mean fasting blood glucoseLink provided by the sponsor.
- Scientific Opinion on Dietary Reference Values for carbohydrates and dietary fibreLink provided by the sponsor.
- Noncommunicable diseasesLink provided by the sponsor.
- Individual participant dataSharing planned: No. The study is designed to look at average responses to the supplement. There is no need to share individual participant data.
Related trials for Postprandial Hyperglycemia
Enrolling by invitation
Development of Anti-Diabetic Nutraceuticals From Legume Seed Coats
Postprandial Hyperglycemia, Type 2 Diabetes
Recruiting
Ultra-processed Food-reducing Intervention and Continuous Glucose Monitoring
Postprandial Glucose, Glucose Levels
Recruiting
Postprandial Metabolome and Metabolic Flexibility
Fasting, Postprandial Hyperglycemia
Active, not recruiting
The Effects of Vegetable Preloading on Postprandial Glycemia, Insulinaemia and Gastric Emptying
Postprandial Hyperglycemia, Insulin High
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Karen Scott, PhD principal investigator
University of Aberdeen
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Galacto-Oligosaccharide and Glucose in people with Postprandial Hyperglycemia and Hyperinsulinemia, run by University of Aberdeen at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 18 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Difference in plasma glucose incremental area under the curve (iAUC) between study arms (time frame: 10 and 5 min before beverage consumption, 15, 30, 45, 60, 90, 120 min after beverage consumption). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06714552, which also lists 18 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Jun 2026; AzTrials last refreshed its copy on 26 Oct 2026.